NCT07012304View on ClinicalTrials.gov

Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2029

Conditions
Chronic Graft Versus Host Disease
Interventions
DRUG

Gecacitinib Hydrochloride Tablets

Gecacitinib hydrochloride tablets are taken orally on an empty stomach. The starting dose is 50 mg once daily (QD). The maximum dose is 100 mg twice daily (BID), and the minimum dose is 50 mg every other day (QOD). Dose adjustments should be made in 50-mg increments or decrements.

Trial Locations (1)

Unknown

RECRUITING

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Yujun DONG

OTHER

NCT07012304 - Gecacitinib for cGVHD: Safety and Efficacy in Patients After ≥2 Lines of Prior Therapy | Biotech Hunter | Biotech Hunter